Stay updated on Elranatamab Study in Relapsed/Refractory Multiple Myeloma Clinical Trial
Sign up to get notified when there's something new on the Elranatamab Study in Relapsed/Refractory Multiple Myeloma Clinical Trial page.

Latest updates to the Elranatamab Study in Relapsed/Refractory Multiple Myeloma Clinical Trial page
- Check6 days agoChange DetectedRevision updated from v3.3.1 to v3.3.2; no changes to study content or page functionality are visible. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check14 days agoChange DetectedRevision label updated from v3.2.0 to v3.3.1 on the page footer; this change does not affect study information or page functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check21 days agoChange DetectedThe notice about government funding and NIH operating status at the top of the page was removed. This change does not affect the study data, results, or navigation on the page.SummaryDifference0.4%

- Check28 days agoNo Change Detected
- Check35 days agoChange DetectedThe latest view shows the addition of Version 39 dated 2025-10-06 in the Record History, while the rest of the page layout remains unchanged. This change does not alter core trial details; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check49 days agoChange DetectedUpdates add a new study status update with date stamping and contacts/locations, and remove an earlier date entry. Core page content related to study status and locations appears to be refreshed.SummaryDifference0.9%

- Check64 days agoChange DetectedThe page has updated its status messaging with a government-operating notice and added a new revision version and date, while removing the previous revision reference. Overall, the significant changes are an updated operating-status notice, a new date (2025-09-29) and a new version (v3.2.0) replacing the old revision (v3.1.0).SummaryDifference11%

Stay in the know with updates to Elranatamab Study in Relapsed/Refractory Multiple Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Elranatamab Study in Relapsed/Refractory Multiple Myeloma Clinical Trial page.